Initial Public Offering

Healthcare
Initial Public Offering

Summary

Baird served as a co-manager on this offering

About

PPD, Inc. (“PPD” or the “Company”) (NASDAQ-GS: PPD) recently completed an initial public offering of 69 million shares of its common stock at a public offering price of $27.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 9 million shares of common stock. The gross proceeds from the offering are $1.863 billion. The proceeds from the offering, together with cash on hand, will be used to redeem in full the Company’s two Senior PIK Toggle Notes, plus redemption premiums and accrued and unpaid interest.

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. PPD’s customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help its customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. PPD is headquartered in Wilmington, North Carolina.
CONTACT US TO LEARN MORE
Healthcare
Initial Public Offering
Date
February 2020
Company
PPD, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share